Role of Radiotherapy in the Management of Pancreatic Adenocarcinoma: Debate and Discordance in Clinical Trials

Authors

  • Avik Mandal All India Institute of Medical Sciences Patna, 801505, India

DOI:

https://doi.org/10.30564/jor.v3i2.3646

Abstract

Pancreatic adenocarcinoma (PAC) is an extremely fatal malignancy with dismal outcome with standard treatment till date. Investigators are constantly in search of optimal treatment approach and radiation therapy (RT) remains in the centre of debate. Human pancreatic cancer cell lines have shown both intrinsic and hypoxia induced radio resistance, and RT has produced conflicting results as well in the various clinical trials. However, most of the American studies continued the use of RT as a potential treatment modality but the European school of thought is widely criticized for their ‘therapeutic nihilism’ towards radiation and faulty clinical trial designs. 

This article has reviewed the available literature on the evolving role of RT for the management of resectable and borderline resectable PAC and has highlighted the increasing trend towards the use of radiotherapy for both adjuvant and neo adjuvant treatment. With the advent of modern RT techniques, the acute and late toxicities are much less than the earlier time, and therefore augmented RT is expected to produce better clinical outcomes for the patients with pancreatic carcinoma.

 

Keywords:

Pancreatic adenocarcinoma, Radiotherapy, Chemoradiotherapy, Clinical trials

References

[1] Pancreas.; 2020. https://gco.iarc.fr/today. Accessed May 29, 2021.

[2] Huang J, Lok V, Ngai CH, et al. Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer. Gastroenterology. 2021;160(3):744-754. doi:10.1053/J.GASTRO.2020.10.007.

[3] Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: Case-control study. Am J Gastroenterol. 2007;102(12):2696-2707. doi:10.1111/j.1572-0241.2007.01510.x

[4] Alsamarrai A, Das SLM, Windsor JA, Petrov MS. Factors That Affect Risk for Pancreatic Disease in the General Population: A Systematic Review and Meta-analysis of Prospective Cohort Studies. Clin Gastroenterol Hepatol. 2014;12(10):1635-1644.e5. doi:10.1016/j.cgh.2014.01.038.

[5] Pourshams A, Sepanlou SG, Ikuta KS, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934-947. doi:10.1016/S2468-1253(19)30347-4.

[6] Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res. 2014;74(11):2913-2921. doi:10.1158/0008-5472.CAN-14-0155.

[7] Katayama ES, Hue JJ, Bajor DL, et al. A comprehensive analysis of clinical trials in pancreatic cancer: What is coming down the pike? Oncotarget. 2020;11(38):3489-3501. doi:10.18632/oncotarget.27727.

[8] RA A, AM L, EM O, RA W, VJ P, PW P. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1751-1756. doi:10.1245/S10434-009-0413-9.

[9] COURTENAY VD, SMITH IE, PECKHAM MJ, STEEL GG. In vitro and in vivo radiosensitivity of human tumour cells obtained from a pancreatic carcinoma xenograft. Nat 1976 2635580. 1976;263(5580):771-772. doi:10.1038/263771a0.

[10] Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys. 1984;10(5):695-712. doi:10.1016/0360-3016(84)90301-8.

[11] Verovski V, Van den Berge D, Soete G, Bols B, Storme G. Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br J Cancer 1996 7411. 1996;74(11):1734-1742. doi:10.1038/bjc.1996.623.

[12] Y S, T K, K K, M T. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother Oncol. 2000;56(2):265-270. doi:10.1016/S0167-8140(00)00181-X.

[13] Schwarz K, Dobiasch S, Nguyen L, Schilling D, Combs SE. Modification of radiosensitivity by Curcumin in human pancreatic cancer cell lines. Sci Reports 2020 101. 2020;10(1):1-10. doi:10.1038/s41598-020-60765-1.

[14] A P, P H, W H, et al. Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2015;150(8):701-710. doi:10.1001/JAMASURG.2015.0668.

[15] Griesbach L, Montag Bettyj, Schnitzerande Grunberg RJ. Studies on Fluorinated Pyrimidines II. Effects on Transplanted Tumors*.; 1958.

[16] Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2(7626):865-867. doi:10.1016/s0140-6736(69)92326-5.

[17] Kaiser MH, Ellenberg SS. Pancreatic Cancer: Adjuvant Combined Radiation and Chemotherapy Following Curative Resection. Arch Surg. 1985;120(8):899-903. doi:10.1001/archsurg.1985.01390320023003.

[18] Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. In: Annals of Surgery. Vol 230. Lippincott, Williams, and Wilkins; 1999:776-784. doi:10.1097/00000658-199912000-00006.

[19] Neoptolemos JP, Stocken DD, Friess H, et al. A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. N Engl J Med. 2004;350(12):1200-1210. doi:10.1056/nejmoa032295.

[20] Koshy MC, Landry JC, Cavanaugh SX, et al. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys. 2005;61(4):965-966. doi:10.1016/j.ijrobp.2004.11.018.

[21] Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA - J Am Med Assoc. 2010;304(10):1073-1081. doi:10.1001/jama.2010.1275.

[22] Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011-1024. doi:10.1016/S0140-6736(16)32409-6.

[23] Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. J Am Med Assoc. 2007;297(3):267-277. doi:10.1001/jama.297.3.267.

[24] Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005). J Clin Oncol. 2008;26(21):3511-3516. doi:10.1200/JCO.2007.15.8782.

[25] Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival: A prospective, single-institution experience. Ann Surg. 1997;225(5):621-636. doi:10.1097/00000658-199705000-00018.

[26] Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients. Ann Surg. 2003;237(1):74-85. doi:10.1097/00000658-200301000-00011.

[27] Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA - J Am Med Assoc. 2008;299(9):1019-1026. doi:10.1001/jama.299.9.1019.

[28] Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18(5):1319-1326. doi:10.1245/s10434-011-1630-6.

[29] Abrams RA, Winter KA, Safran H, et al. Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial. Am J Clin Oncol Cancer Clin Trials. 2020;43(3):173-179. doi:10.1097/COC.0000000000000633

[30] RP M, KY B, JS T, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372-377. doi:10.1097/SLA.0000000000000378

[31] Versteijne E, Group on behalf of the DPC, Vogel JA, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946-958. doi:10.1002/BJS.10870.

[32] E V, CH van E, CJ P, et al. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials. 2016;17(1). doi:10.1186/S13063-016-1262-Z.

[33] E V, M S, K G, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38(16):1763-1773. doi:10.1200/JCO.19.02274.

[34] Janssen QP, van Dam JL, Bonsing BA, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 2021 211. 2021;21(1):1-8. doi:10.1186/S12885-021-08031-Z.

[35] Suker M, Nuyttens JJ, Eskens FALM, et al. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). EClinicalMedicine. 2019;17:100200. doi:10.1016/J.ECLINM.2019.10.013.

[36] Cohen DJ, Medina B, Du KL, et al. Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC). https://doi.org/101200/JCO20193715_supplTPS4163. 2019;37(15_suppl):TPS4163-TPS4163. doi:10.1200/JCO.2019.37.15_SUPPL.TPS4163.

[37] Oar A, Lee M, Le H, et al. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer 2021 211. 2021;21(1):1-11. doi:10.1186/S12885-021-08666-Y.

[38] Search of: SBRT | Pancreatic Cancer - List Results - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=Pancreatic+Cancer&term=SBRT&cntry=&state=&city=&dist=. Accessed August 30, 2021.

Downloads

How to Cite

Mandal, A. (2021). Role of Radiotherapy in the Management of Pancreatic Adenocarcinoma: Debate and Discordance in Clinical Trials. Journal of Oncology Research, 3(2), 40–45. https://doi.org/10.30564/jor.v3i2.3646

Issue

Vol. 3 , Iss. 2 (July 2021)

Article Type

Reviews

License

Copyright and Licensing

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

Journal of Oncology Research publishes accepted manuscripts under Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Authors who submit their papers for publication by Journal of Oncology Research agree to have the CC BY-NC 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for non-commercial use. As long as you follow the license terms and original source is properly cited, anyone may copy, redistribute the material in any medium or format, remix, transform, and build upon the material.

License Policy for Reuse of Third-Party Materials

If a manuscript submitted to the journal contains the materials which are held in copyright by a third-party, authors are responsible for obtaining permissions from the copyright holder to reuse or republish any previously published figures, illustrations, charts, tables, photographs, and text excerpts, etc. When submitting a manuscript, official written proof of permission must be provided and clearly stated in the cover letter.
The editorial office of the journal has the right to reject/retract articles that reuse third-party materials without permission.

Journal Policies on Data Sharing

We encourage authors to share articles published in our journal to other data platforms, but only if it is noted that it has been published in this journal.